• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Legend Biotech Corporation - American Depositary Shares (NQ: LEGN )

    32.39 -0.39 (-1.19%)
    Streaming Delayed Price Updated: 12:14 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 223,627
    Open 32.65
    Bid (Size) 32.33 (4)
    Ask (Size) 32.43 (2)
    Prev. Close 32.78
    Today's Range 32.22 - 33.31
    52wk Range 32.08 - 70.13
    Shares Outstanding 308,456,852
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    (LEGN) - Analyzing Legend Biotech's Short Interest
    Via Benzinga

    Performance

    YTD
    -45.19%
    -45.19%
    1 Month
    -23.93%
    -23.93%
    3 Month
    -30.86%
    -30.86%
    6 Month
    -27.47%
    -27.47%
    1 Year
    -44.82%
    -44.82%

    More News

    Read More
    Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)
    Via Benzinga
    Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 12, 2024
    Via Benzinga
    Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    9 Analysts Have This To Say About Legend Biotech
    Via Benzinga
    CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Where Legend Biotech Stands With Analysts
    Via Benzinga
    Peering Into Legend Biotech's Recent Short Interest
    Via Benzinga
    Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
    Via Benzinga
    Looking Into Legend Biotech's Recent Short Interest
    Via Benzinga
    Legend Biotech Appoints Alan Bash as President of CARVYKTI®
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
    Via Benzinga
    Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
    Via Benzinga
    CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
    Via Investor's Business Daily
    Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
    From Legend Biotech USA Inc.
    Via GlobeNewswire
    Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.